Sunitinib, a drug for the treatment of renal cell carcinoma, activates the NF-κB signaling pathway through the IRE1α/TRAF2/IKKβ axis of the ER stress response, enhancing the expression of IL-6, IL-8, and TNF-α. Here, ERN1 is linked to hereditary clear cell renal cell carcinoma.